ReviewFrontiers in immunology2019
The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- The Role of Gut Microbiome in the Pathogenesis of Multiple Sclerosis and Related Disorders.Cells · 2023Pooled it
- What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Efficacy of diet on fatigue, quality of life and disability status in multiple sclerosis patients: rapid review and meta-analysis of randomized controlled trials.BMC neurology · 2022Pooled it
- Influence of a High-Impact Multidimensional Rehabilitation Program on the Gut Microbiota of Patients with Multiple Sclerosis.International journal of molecular sciences · 2021Trial
- Intrathecal Anti-Journal of clinical medicine · 2025Article
- The Possible Role of Metformin and Fibroblast Growth Factor-21 in Multiple Sclerosis Neuropathology: Birds of a Feather Flock Together.The European journal of neuroscience · 2025Review
- Article
- Dietary index for gut microbiota and its protective role against kidney stones: evidence of diabetes as a mediator from NHANES cross-sectional data.Frontiers in nutrition · 2025Article
- Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects.Pharmacological reports : PR · 2024Review
- Autoimmune Diseases Following Environmental Disasters: A Narrative Review of the Literature.Healthcare (Basel, Switzerland) · 2024Review
- Article
- Role of fenofibrate in multiple sclerosis.European journal of medical research · 2024Review
- Involvement and repair of epithelial barrier dysfunction in allergic diseases.Frontiers in immunology · 2024Review
- Intestinal Barrier Function and Neurodegenerative Disease.CNS & neurological disorders drug targets · 2024Review
- Hyperresponsiveness of Corticoid-Resistant Th17/Tc-17 Cells to TLR-2 and TLR-4 Ligands is a Feature of Multiple Sclerosis Patients at Higher Risk of Therapy Failure.Journal of inflammation research · 2024Article
- Comparative analysis of human gut- and blood-derived mononuclear cells: contrasts in function and phenotype.Frontiers in immunology · 2024Article
- Oral vancomycin treatment suppresses gut trypsin activity and preserves intestinal barrier function during EAE.iScience · 2023Article
- Food, gut barrier dysfunction, and related diseases: A new target for future individualized disease prevention and management.Food science & nutrition · 2023Review
- Treatment with the Olive Secoiridoid Oleacein Protects against the Intestinal Alterations Associated with EAE.International journal of molecular sciences · 2023Article
- Fecal Microbiota Underlying the Coexistence of Schizophrenia and Multiple Sclerosis in Chinese Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut barrier consists of several components, including the mucus layer, made of mucins and anti-bacterial molecule, the epithelial cells, connected by tight junction proteins, and a mixed population of cells involved in the interplay with microbes, such as M cells, elongations of "antigen presenting cells" dwelling the lamina propria, intraepithelial lymphocytes and Paneth cells secreting anti-bacterial peptides. Recently, the influence of intestinal permeability (IP) changes on organs far from gut has been investigated, and IP changes in multiple sclerosis (MS) have been described. A related topic is the microbiota dysfunction that underpins the development of neuroinflammation in animal models and human diseases, including MS. It becomes now of interest to better understand the mechanisms through which IP changes contribute to pathophysiology of neuroinflammation. The following aspects seem of relevance: studies on other biomarkers of IP alterations; the relationship with known risk factors for MS development, such as vitamin D deficiency; the link between blood brain barrier and gut barrier breakdown; the effects of IP increase on microbial translocation and microglial activation; the parallel patterns of IP and neuroimmune changes in MS and neuropsychiatric disorders, that afflict a sizable proportion of patients with MS. We will also discuss the therapeutic implications of IP changes, considering the impact of MS-modifying therapies on gut barrier, as well as potential approaches to enhance or protect IP homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.